CONCERT PHARMACEUTICALS INC. Daily Stock Analysis

Daily Stock Analysis, CNDT, CONCERT PHARMACEUTICALS INC, priceseries

CONCERT PHARMACEUTICALS INC. Daily Stock Analysis
Stock Information
Open
4.25
Close
4.16
High
4.30
Low
4.14
Previous Close
4.24
Daily Price Gain
-0.08
YTD High
6.32
YTD High Date
Jan 6, 2022
YTD Low
4.12
YTD Low Date
Feb 17, 2022
YTD Price Change
-1.44
YTD Gain
-25.71%
52 Week High
8.50
52 Week High Date
Jun 9, 2021
52 Week Low
4.12
52 Week Low Date
Feb 17, 2022
52 Week Price Change
-2.55
52 Week Gain
-38.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 21. 2018
17.86
Mar 22. 2018
19.63
21 Trading Days
9.93%
Link
LONG
Aug 2. 2018
18.64
Sep 18. 2018
22.68
32 Trading Days
21.66%
Link
LONG
Jan 4. 2019
10.99
Feb 28. 2019
14.64
37 Trading Days
33.21%
Link
LONG
Mar 27. 2020
2.04
Apr 1. 2020
2.14
3 Trading Days
5.02%
Link
LONG
Apr 6. 2020
2.12
Apr 15. 2020
2.24
6 Trading Days
5.66%
Link
LONG
Jun 2. 2020
2.39
Jun 11. 2020
2.70
7 Trading Days
12.77%
Link
LONG
Aug 3. 2020
2.14
Aug 20. 2020
3.60
13 Trading Days
68.44%
Link
LONG
Nov 13. 2020
3.91
Nov 30. 2020
4.31
10 Trading Days
10.26%
Link
LONG
Dec 4. 2020
4.53
Dec 18. 2020
5.04
10 Trading Days
11.18%
Link
LONG
May 26. 2021
7.36
Jun 15. 2021
7.97
13 Trading Days
8.26%
Link
Company Information
Stock Symbol
CNDT
Exchange
NASDAQ
Company URL
http://www.concertpharma.com
Company Phone
781-860-0045
CEO
Roger D. Tung
Headquarters
Massachusetts
Business Address
99 HAYDEN AVENUE, SUITE 500, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001367920
About

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs for renal disease, CNS disorders, inflammation and hematologic disorders. It also creates novel medicines that address commercially important needs by applying its deuterated chemical entity platform to compounds with well-characterized pharmacological activity. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The company's clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading